

## Mahajan, Vinay

---

**From:** Office, John Tsai (Gen)  
**Sent:** Friday, October 12, 2018 1:33 PM  
**To:** Mahajan, Vinay  
**Subject:** Organizational Announcement



Dear Colleagues,

As I have the pleasure to meet and get to know more and more of you, I am regularly reminded of the immense talent we have in GDD, a talent and a passion for science and innovation that fuel an incredible pipeline of medicines that transform people's lives. To continue to reimagine medicine, we need to complement that talent and passion with a robust, focused portfolio strategy. The first step to achieve that was the separation of the Portfolio Strategy and Innovation team into two stand-alone functions – Portfolio Strategy and Data & Digital. I am now pleased to announce that **Amit Agrawal** is appointed *Head Portfolio Strategy*, effective October 15, 2018.

Building on the strong foundation established by Portfolio Strategy team, Amit will drive the GDD portfolio strategy in partnership with me to deliver an innovative, impactful and

sustainable pipeline for Novartis. He will lead the implementation of methods and systems that improve decision making about the pipeline, drive the simplification of our drug development processes, and continue to strengthen our project management and functional capabilities.

Amit brings more than 17 years of biopharma and life science experience. He joins us from Amgen, where he was *Executive Director, Head of Corporate Strategy*. Prior to Amgen, Amit worked with McKinsey and Company and finished a Post-Doctoral fellowship focused on siRNA delivery, at Massachusetts Institute of Technology, US. Amit has a PhD in Biomedical Engineering from the Georgia Institute of Technology, US, and a Master of Science in Chemistry from the Indian Institutes of Technology, Kanpur. Amit will relocate with his family from California to Basel. He will become a member of the Development Committee of Novartis (DCN).

Key to the successful development of the portfolio strategy are the Global Program Heads (GPH), who ensure coordination and strategic execution of our clinical programs. Given the critical leadership role of this group, I have asked **Pascale Burtin** to take on a new role as *Head, Global Program Head Excellence*. Pascale will be accountable for building and connecting the GPH community and for further strengthening the interface between NIBR, as well as ensuring the success of the GPTs. She will report to Amit, while the GPHs will continue to report into the Development Units. I would like to thank Pascale for her valuable contributions as *ad-interim Head of Portfolio Strategy* and I look forward to continuing to work with her in this important role.

The success of GDD is dependent on the strength of our regions and countries. Only by working closely with and drawing on the strength of our sites can we advance our organization. To bolster these efforts, **Arno Tellmann**, previously *Global Head Pharmacovigilance, Strategy and Operations*, is appointed *Head Global Development India*, effective November 1, 2018. Arno will lead the strategic growth of the functions in Hyderabad, ensuring timely and high quality support for the GDD portfolio. He will champion the strategy for GDD India and head the GDD India leadership team.

With Development Operations being the largest significant presence in India, Arno will report to **Badhri Srinivasan**, *Head of Global Development Operations*. He will also be a member of the Country Executive Council (CEC) India. He will relocate from Basel to Hyderabad in January 2019.

Arno succeeds **Subodh Deshmukh**, who is appointed *Head, Global Product Development, Sandoz*, effective November 1, 2018. I would like to thank Subodh for his leadership of GDD India. In collaboration with the DCN and the India Executive Committee, he has been instrumental in establishing a globally integrated drug development organization in Hyderabad and building a strong leadership team in India. He leaves GDD India well positioned to play a key role in accelerating the development of innovative and impactful medicines.

China, as the second largest pharma market after the US, is also a priority country for GDD and as such, it is vital that we continue to focus on maximizing the value of our portfolio in China. I have therefore transferred the reporting line for GDD China from **Florian Bieber**, Head, Clinical Development and Analytics (CD&A) to **Eric Hughes**, Head, Immunology, Hepatology and Dermatology DU. This realignment will enable Florian to continue his focus on building capabilities across CD&A and gives Eric the opportunity to further shape our China portfolio, advancing innovation in this market and particularly the essential drugs (including Cosentyx) that China's State FDA have highlighted for accelerated approval. **Rae Yuan** will continue in her role as Head of GDD China and will report to Eric. I would like to thank Florian and Rae for all the work they have done to bring the organization to where it is today, including the delivery of a record number of New Drug Applications (NDAs) in 2017.

Please join me in wishing Amit, Pascale, Arno, and Subodh every success in their new roles.

Best regards

John Tsai

For internal use only and not to be shown, distributed or disseminated outside of Novartis



